Search results for "Chronic Hepatitis"

showing 10 items of 159 documents

Long-Term Follow-Up of Patients with Chronic Hepatitis C after Interferon-Alpha Treatment

1996

In this study, 72 patients with chronic hepatitis C virus (HCV) were followed prospectively for a mean period of 27 months after interferon treatment. Fifty-seven percent (20/35) of the patients with complete response, 18/20 with HCV-RNA-negative serum, had a sustained biochemical remission. Reactivation was seen in 43% of these patients after a mean follow-up of 7.3 months. A late relapse after more than 12 months of follow-up occurred in only 2/15 patients. Patients with a long-term complete response had significantly lower pretreatment serum HCV RNA levels than complete responders with relapse (106,239 vs. 345,649 mEq/ml, p = 0.0213). A delayed sustained biochemical remission was seen in…

AdultMalemedicine.medical_specialtyLong term follow upmedicine.medical_treatmentAlpha interferonHepacivirusGastroenterologyVirusChronic hepatitisInterferonInternal medicinemedicineHumansProspective StudiesInterferon alfaAgedbusiness.industryGastroenterologyInterferon-alphaImmunotherapyMiddle AgedHepatitis CChronic DiseaseImmunologyRNA ViralFemaleViral diseasebusinessFollow-Up Studiesmedicine.drugDigestion
researchProduct

Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients

2012

Background: Hepatitis C virus infection is characterised by enhanced oxidative stress, which can be measured quantitatively by plasma oxysterol concentration. These molecules may affect lipid metabolism through the activation of Liver X Receptors. Hepatitis C virus exploits host lipid metabolism to facilitate its replication and diffusion. In our study we aimed to evaluate and highlight the potential pathogenetic role of oxysterols, 7-ketocholesterol and 7-β-hydroxycholesterol, in hepatitis C virus-related lipid dysmetabolism. Methods: The study was performed in 42 patients with chronic hepatitis C (93% genotype 1b) and 38 non-alcoholic fatty liver disease patients. Plasma oxysterols 7-keto…

AdultMalemedicine.medical_specialtyOxysterolHepatitis C virusHepacivirusIsotope dilutionmedicine.disease_causechronic hepatitis c infection; lipid metabolism; non-alcoholic fatty liver disease; oxidative stressNon-alcoholic Fatty Liver DiseaseInternal medicinemedicinepolycyclic compoundsoxysterol hcv nafldHumansoxysterols sterols cholesterol mass spectrometry metabolomicsLiver X receptorKetocholesterolsHepatologybusiness.industryFatty liverGastroenterologyLipid metabolismHepatitis CCholesterol LDLMiddle Agedmedicine.diseaseHepatitis CChronic hepatitis C infectionHydroxycholesterolsFatty LiverOxidative StressEndocrinologyLipid metabolismBiochemistryMultivariate AnalysisLinear Modelslipids (amino acids peptides and proteins)FemalebusinessOxidative stress
researchProduct

Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.

2006

: Background/Aim: Liver steatosis (LS) has been variably associated with chronic hepatitis C (CHC) but whether it affects sustained virological response to antiviral treatment and by what mechanisms is a question still under debate, at least for some genotypes. The aim of this work was to assess the frequency of LS, its relationship with host and viral factors and to what extent it can influence the response to antiviral combination therapy with pegylated interferon (INF)+ribavirin in a group of patients with CHC from a single center. Patients: One hundred and twelve patients with histologically proven CHC were treated with Peg INF-α 2a 180 μg a week subcutaneously for 48 weeks plus ribavir…

AdultMalemedicine.medical_specialtyPathologyAgingCombination therapyGenotypeHepatitis C virusantiviral treatmentHepacivirusInterferon alpha-2Single Centermedicine.disease_causeGastroenterologyAntiviral AgentsSeverity of Illness IndexBody Mass IndexPolyethylene Glycolsliver steatosischemistry.chemical_compoundPegylated interferonInternal medicineGenotypeRibavirinmedicinechronic hepatitis CHumansAspartate AminotransferasesHepatologybusiness.industryRibavirinInterferon-alphaAlanine Transaminasegamma-GlutamyltransferaseHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsFatty LiverTreatment OutcomechemistryLiverDrug Therapy CombinationFemaleSteatosisbusinessBody mass indexmedicine.drugLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Ultrasound detection of abdominal lymphadenomegaly in subjects with hepatitis C virus infection and persistently normal transaminases: a predictive i…

1998

The indications for liver biopsy in anti-HCV-positive patients with persistently normal alanine aminotransferase levels are not clearly established. Recent studies have correlated the presence of abdominal lymphoadenomegaly with disease severity in patients with chronic hepatitis C. Our study aimed to evaluate the frequency of abdominal lymphoadenomegaly in an anti-HCV positive blood donor population with persistently normal alanine aminotransferase and the relationship of abdominal lymphoadenomegaly with the severity of liver changes.Eighty-six anti-HCV positive blood donors (58 M, 28 F) with normal alanine aminotransferase were followed up for a median of 31 months (range 12-50). To evalu…

AdultMalemedicine.medical_specialtyPathologySettore MED/09 - Medicina InternaLogistic ModelAdolescentPrognosiHepatitis C virusHepacivirusBiopsyPopulationBlood Donorsmedicine.disease_causeGastroenterologyRegression AnalysiInternal medicineAbdomenmedicineHumanseducationLymphatic Diseasesabdominal lymph nodes; chronic hepatitis c; normal transaminase; ultrasoundUltrasonographyeducation.field_of_studyHepatologymedicine.diagnostic_testbiologybusiness.industryUltrasoundAlanine TransaminaseHepatitis C AntibodiesHepatitis C ChronicMiddle Agedbiology.organism_classificationPrognosismedicine.anatomical_structureLogistic ModelsLiverLiver biopsyAbdomenRegression AnalysisFemaleViral diseaseLiver functionLymphatic DiseaseHepatitis C AntibodiebusinessHumanJournal of hepatology
researchProduct

Insulin-resistance HCV infection-related affects vascular stiffness in normotensives

2015

BACKGROUND AND AIMS. Arterial stiffness evaluated as pulse wave velocity, is an early marker of vascular damage and an independent predictor for cardiovascular events. We investigated if the insulin resistance/hyperinsulinemia chronic hepatitis C virus infection-related could influence arterial stiffness. METHODS. We enrolled 260 outpatients matched for age, body mass index, gender, ethnicity: 52 with never-treated uncomplicated chronic hepatitis C virus infection (HCV(+)), 104 never-treated hypertensives (HT) and 104 healthy subjects (NT). Pulse wave velocity was evaluated by a validated system employing high-fidelity applanation tonometry. We also measured: fasting plasma glucose and insu…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentArterial stiffness; Chronic hepatitis C virus infection; Insulin resistanceInsulin resistance; chronic hepatitis C virus infection; arterial stiffnessBlood PressurePulse Wave AnalysisBody Mass Indexchemistry.chemical_compoundVascular StiffnessInsulin resistanceRisk FactorsHyperinsulinismInternal medicinemedicineHyperinsulinemiaHumansInsulinPulse wave velocityCreatinineTriglyceridebusiness.industryInsulinInsulin resistanceHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseArterial stiffnearterial stiffnessEndocrinologychemistryCase-Control StudiesHypertensionLinear ModelsArterial stiffnessFemaleCardiology and Cardiovascular MedicinebusinessChronic hepatitis C virus infection
researchProduct

Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.

2006

BACKGROUND The efficacy of consensus interferon (CIFN), a synthetic IFN with optimised in vitro activity, was assessed in chronic hepatitis C virus (HCV) patients who had failed the pretreatment with interferon-alpha (IFNalpha) and ribavirin. METHODS One hundred and three patients after non-response (n=69) or relapse (n=34) to IFNalpha+/-ribavirin were randomly assigned to high-dose induction (CIFN 27-->9 microg daily for 24 weeks, 9 microg t.i.w. for 24 weeks) or low-dose treatment (CIFN 18 microg t.i.w. for 12 weeks, 9 microg t.i.w. for 36 weeks); each with ribavirin 800 mg/day. Follow-up was 24 weeks. RESULTS Non-responder patients treated with high-dose induction had higher early virolo…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentConsensus interferonAlpha interferonHepacivirusGastroenterologyAntiviral AgentsVirusVirological responsechemistry.chemical_compoundChronic hepatitisInternal medicineRibavirinMedicineHumansIn patientDosingProspective StudiesAgedHepatologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis C ChronicMiddle AgedViral Loaddigestive system diseasesTreatment OutcomechemistryResearch DesignImmunologyFemaleInterferonsbusinessBiomarkersFollow-Up StudiesLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Predicting Early and Sustained Virological Responses in Prior Nonresponders to Pegylated Interferon alpha-2b Plus Ribavirin Retreated With Peginterfe…

2013

GOALS: To evaluate the predictive value of complete early virological response (cEVR) on sustained virological response (SVR) following retreatment with peginterferon alpha-2a (40 kDa) plus ribavirin in previous nonresponders to peginterferon alpha-2b (12 kDa). BACKGROUND: In the randomized multinational retreatment with Pegasys in patients not responding to PegIntron therapy study, a 72-week regimen of peginterferon alpha-2a (40 kDa) plus ribavirin improved SVR rates over a standard 48-week regimen in previous nonresponders to peginterferon alpha-2b (12 kDa). cEVR, defined as hepatitis C virus RNA <50 IU/mL at treatment week 12, was an important predictor of SVR. STUDY: We conducted an exp…

AdultMalemedicine.medical_specialtyTime FactorsInterferon alpha-2Antiviral therapyAntiviral AgentsGastroenterologyPolyethylene Glycolslaw.inventionchemistry.chemical_compoundPharmacotherapyRandomized controlled trialnonresponderPredictive Value of TestslawInternal medicineRibavirinchronic hepatitis CHumansMedicinepeginterferonAdverse effectRandomized Controlled Trials as Topicbusiness.industryRibavirinGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasepeginterferon; chronic hepatitis C; nonresponder; retreatment; sustained virological responseRecombinant Proteinsdigestive system diseasesRegimenTreatment OutcomechemistryPredictive value of testsRelative riskRetreatmentDrug Therapy CombinationFemalesustained virological responsebusinessJournal of Clinical Gastroenterology
researchProduct

Serum malondialdehyde: possible use for the clinical management of chronic hepatitis C patients

1998

Serum lipid peroxidation products are increased in inflammatory liver disease and, as we previously reported, also in chronic hepatitis C. We have performed a specific assay of malondialdehyde, the reported most abundant product of lipid peroxidation, in serum of twenty four chronic hepatitis C patients, before, during, and after interferon treatment. Liver biopsies were performed in each patient before and after interferon treatment. The results show higher serum malondialdehyde values in chronic hepatitis C patients than healthy subjects (n = 68) before interferon treatment (p < .001). Mean value of serum malondialdehyde levels after interferon treatment was significantly lower than befor…

Adultmedicine.medical_specialtyHepatitis C virusmedicine.disease_causeBiochemistryGastroenterologyLipid peroxidationchemistry.chemical_compoundLiver diseaseChronic hepatitisInterferonMalondialdehydePhysiology (medical)Internal medicineBiopsymedicineHumansmedicine.diagnostic_testbusiness.industryInterferon-alphaAlanine TransaminaseHepatitis C ChronicMiddle AgedMalondialdehydemedicine.diseasechemistryImmunologybusinessOxidative stressmedicine.drugFree Radical Biology and Medicine
researchProduct

Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy

2017

Background: Gender differences in chronic liver disease (CLD) have been partially investigated. To extend the present knowledge, we evaluated 12,263 patients with CLD enrolled in two national surveys (9997 in 2001 and 2557 in 2014). Methods: The two surveys prospectively recruited patients aged ≥ 18 referring to Italian liver units throughout the country using a similar clinical approach and analytical methods. Results: The overall male to female ratio (M/F) was 1.4 (7138/5124). Compared with females, males were significantly more likely to be younger (52.9 vs. 58.7 yrs.), with HBV infection alone (13.2% vs. 9.2%) and with alcoholic liver disease alone (11.4% vs. 6.9%), but less likely t…

Alcoholic liver diseasePathologyCirrhosisliver diseasesHepatocellular carcinomaPrevalenceChronic liver diseaseGastroenterology0302 clinical medicinecohort studiesEpidemiologymiddle aged030212 general & internal medicinehumansChronic liver diseasesHBV infectionChronic hepatitisadultChronic liver diseaseGeneral MedicineHepatitis CHepatitis BHCV infectionagedInfectious DiseasesItalyyoung adult030211 gastroenterology & hepatologyCohort studyMicrobiology (medical)medicine.medical_specialtyprevalence03 medical and health sciencesInternal medicinemedicineLiver Diseases AlcoholicAlcoholic liver diseases; Chronic hepatitis; Chronic liver diseases; HBV infection; HCV infection; Hepatocellular carcinoma; Microbiology (medical); Infectious DiseasesAlcoholic liver diseases; Chronic hepatitis; Chronic liver diseases; HBV infection; HCV infection; Hepatocellular carcinomabusiness.industryAlcoholic liver diseaseAlcoholic liver diseasesmedicine.diseaseprospective studiessex factorsChronic hepatitihepatitis Bhepatitis Cbusinesschronic diseasealcoholic liver diseases; chronic hepatitis; chronic liver diseases; HBV infection; HCV infection; hepatocellular carcinoma; adult; aged; chronic disease; cohort studies; hepatitis B; hepatitis C; humans; Italy; liver diseases; liver diseases alcoholic; middle aged; prevalence; prospective studies; sex factors; young adultalcoholic
researchProduct

A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B

2010

Antiviral treatmentRandomized trialChronic hepatitis BHBeAg negative
researchProduct